BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32310254)

  • 1. Association of Dermatomyositis Sine Dermatitis With Anti-Nuclear Matrix Protein 2 Autoantibodies.
    Inoue M; Tanboon J; Hirakawa S; Komaki H; Fukushima T; Awano H; Tajima T; Yamazaki K; Hayashi R; Mori T; Shibuya K; Yamanoi T; Yoshimura H; Ogawa T; Katayama A; Sugai F; Nakayama Y; Yamaguchi S; Hayashi S; Noguchi S; Tachimori H; Okiyama N; Fujimoto M; Nishino I
    JAMA Neurol; 2020 Jul; 77(7):872-877. PubMed ID: 32310254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case Report on Rare Presentation of Sporadic Disease: Dermatomyositis Sine Dermatitis-Diagnosis and Management.
    Vahora I; Lingireddy A; Nadella S; Trivedi B; Dihowm F
    J Investig Med High Impact Case Rep; 2022; 10():23247096221121403. PubMed ID: 36050930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.
    Deakin CT; Yasin SA; Simou S; Arnold KA; Tansley SL; Betteridge ZE; McHugh NJ; Varsani H; Holton JL; Jacques TS; Pilkington CA; Nistala K; Wedderburn LR;
    Arthritis Rheumatol; 2016 Nov; 68(11):2806-2816. PubMed ID: 27214289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Two cases of anti-nuclear matrix protein 2 antibody-positive dermatomyositis sine dermatitis with severe diffuse subcutaneous edema and dysphagia].
    Takahashi Y; Takamiya M; Ichimura Y; Okiyama N; Nishino I; Morimoto N
    Rinsho Shinkeigaku; 2023 Nov; 63(11):737-742. PubMed ID: 37880118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2.
    Ishikawa A; Muro Y; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Jul; 51(7):1181-7. PubMed ID: 22427409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
    Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
    Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y; Ishikawa A; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perimysial microarteriopathy in dermatomyositis with anti-nuclear matrix protein-2 antibodies.
    Liu Y; Zheng Y; Gang Q; Xie Z; Jin Y; Zhang X; Deng X; Hao H; Gao F; Zhang Z; Xiong H; Zhang W; Wang Z; Yuan Y
    Eur J Neurol; 2020 Mar; 27(3):514-521. PubMed ID: 31571350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermatomyositis: Muscle Pathology According to Antibody Subtypes.
    Tanboon J; Inoue M; Saito Y; Tachimori H; Hayashi S; Noguchi S; Okiyama N; Fujimoto M; Nishino I
    Neurology; 2022 Feb; 98(7):e739-e749. PubMed ID: 34873015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.
    Valenzuela A; Chung L; Casciola-Rosen L; Fiorentino D
    JAMA Dermatol; 2014 Jul; 150(7):724-9. PubMed ID: 24869801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
    Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
    Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.
    Nguyen M; Do V; Yell PC; Jo C; Liu J; Burns DK; Wright T; Cai C
    Acta Neuropathol Commun; 2020 Aug; 8(1):125. PubMed ID: 32758284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myositis autoantibodies.
    Casciola-Rosen L; Mammen AL
    Curr Opin Rheumatol; 2012 Nov; 24(6):602-8. PubMed ID: 22955022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two young-adult female cases of dermatomyositis with antibodies for transcriptional intermediary factor 1-γ.
    Matsuura E; Ishiguro N; Katsumata Y; Urano W; Yamanaka H; Kondo M; Kuwana M; Kaji K; Hamaguchi Y; Fujimoto M; Kawashima M
    Eur J Dermatol; 2012; 22(5):668-71. PubMed ID: 22992252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features.
    Troyanov Y; Targoff IN; Payette MP; Raynauld JP; Chartier S; Goulet JR; Bourré-Tessier J; Rich E; Grodzicky T; Fritzler MJ; Joyal F; Koenig M; Senécal JL
    Medicine (Baltimore); 2014 Nov; 93(24):318-332. PubMed ID: 25500701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.
    Albayda J; Pinal-Fernandez I; Huang W; Parks C; Paik J; Casciola-Rosen L; Danoff SK; Johnson C; Christopher-Stine L; Mammen AL
    Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1771-1776. PubMed ID: 28085235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
    Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
    Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research progress on the dermatomyositis specific autoantibodies and malignancy associated dermatomyositis.
    Xu Y; Yang Y; Fan S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Dec; 48(12):1890-1898. PubMed ID: 38448383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis.
    Uruha A; Allenbach Y; Charuel JL; Musset L; Aussy A; Boyer O; Mariampillai K; Landon-Cardinal O; Rasmussen C; Bolko L; Maisonobe T; Leonard-Louis S; Suzuki S; Nishino I; Stenzel W; Benveniste O
    Neuropathol Appl Neurobiol; 2019 Aug; 45(5):513-522. PubMed ID: 30267437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.
    Wolstencroft PW; Casciola-Rosen L; Fiorentino DF
    JAMA Dermatol; 2018 Oct; 154(10):1199-1203. PubMed ID: 30140893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.